Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ADOLFO FERNANDEZ OBREGON

NPI
1316944051
CMS profile
14645
Location
HOBOKEN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,610.97

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,610.97 109

By paying entity

PY2019 · entire year · sorted by reported total

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ADOLFO FERNANDEZ OBREGON

NPI 1316944051 · CMS profile ID 14645

HOBOKEN, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316944051?year=2019&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ADOLFO FERNANDEZ OBREGON, NPI 1316944051, CMS profile ID 14645. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316944051?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ADOLFO FERNANDEZ OBREGON, NPI 1316944051, CMS profile ID 14645. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316944051?year=2019&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ADOLFO FERNANDEZ OBREGON, NPI 1316944051, CMS profile ID 14645, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–109 of 109 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1316944051?year=2019&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $1,610.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–109 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $12.7901/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687258737 CMS
Galderma Laboratories, L.P. $11.2301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687678781 CMS
Lilly USA, LLC $13.5501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657649875 CMS
Janssen Scientific Affairs, LLC $11.6301/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657592715 CMS
PFIZER INC. $13.2001/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671845631 CMS
Biofrontera Inc. $12.8601/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667980285 CMS
Janssen Biotech, Inc. $13.9001/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658424277 CMS
Janssen Biotech, Inc. $16.6201/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658424273 CMS
Sun Pharmaceutical Industries Inc. $13.0101/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704648721 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,610.97 109
PY2020 $7,383.55 119
PY2021 $2,248.62 99
PY2022 $3,834.79 90
PY2023 $10,929.28 130
PY2024 $8,485.00 105
PY2025 $3,434.46 99

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $604,534.71 67
PY2024 Recipient $104.58 1
PY2024 Principal investigator $76,248.12 17
PY2023 Recipient $2,854.70 9
PY2023 Principal investigator $19,808.00 4
PY2022 Principal investigator $294,669.90 13
PY2021 Principal investigator $14,002.02 10
PY2020 Principal investigator $24,809.28 11
PY2019 Recipient $8,522.00 2
PY2019 Principal investigator $34,794.25 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

67 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 12/22/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112807
Principal investigator 1 Hoffmann-La Roche Limited $95.00 12/11/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583771
Principal investigator 1 Hoffmann-La Roche Limited $6,360.00 12/11/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583775
Principal investigator 1 Hoffmann-La Roche Limited $500.00 12/11/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583779
Principal investigator 1 SANOFI US SERVICES INC. $390.00 12/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112747
Principal investigator 1 SANOFI US SERVICES INC. $240.00 12/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112752
Principal investigator 1 Novartis Pharmaceuticals Corporation $720.59 11/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH HOBOKEN
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190311255
Principal investigator 1 SANOFI US SERVICES INC. $881.30 11/10/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112706
Principal investigator 1 SANOFI US SERVICES INC. $20,532.00 11/10/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112718
Principal investigator 1 Amgen Inc. $12,000.00 11/06/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Re-randomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO) No dispute reported 06/30/2026 1246640059
Principal investigator 1 SANOFI US SERVICES INC. $791.30 11/04/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112693
Principal investigator 1 SANOFI US SERVICES INC. $410.60 10/27/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112687
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,954.14 10/14/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH HOBOKEN
A Multicenter, Randomized, Participant- and Investigator -Blinded, Placebo-controlled, Phase 2a Study to Assess the Efficacy, Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190311251
Principal investigator 1 SANOFI US SERVICES INC. $931.30 10/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112633
Principal investigator 1 SANOFI US SERVICES INC. $675.00 09/22/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112585
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 09/22/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112590
Principal investigator 1 SANOFI US SERVICES INC. $17,410.00 09/15/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112563
Principal investigator 1 SANOFI US SERVICES INC. $3,000.00 09/08/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112556
Principal investigator 1 Incyte Corporation $15,000.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512178
Principal investigator 1 Incyte Corporation $750.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512183
Principal investigator 1 Incyte Corporation $2,690.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512189
Principal investigator 1 Incyte Corporation $1,000.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512194
Principal investigator 1 Incyte Corporation $1,750.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512199
Principal investigator 1 Incyte Corporation $1,500.00 09/05/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240512205
Principal investigator 1 SANOFI US SERVICES INC. $501.30 09/03/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112542
Principal investigator 1 SANOFI US SERVICES INC. $3,396.30 08/25/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112577
Principal investigator 1 SANOFI US SERVICES INC. $750.00 08/04/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112485
Principal investigator 1 SANOFI US SERVICES INC. $26.30 07/21/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112431
Principal investigator 1 SANOFI US SERVICES INC. $475.00 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112407
Principal investigator 1 SANOFI US SERVICES INC. $4,926.00 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112443
Principal investigator 1 SANOFI US SERVICES INC. $745.00 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112449
Principal investigator 1 SANOFI US SERVICES INC. $24.30 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113370
Principal investigator 1 SANOFI US SERVICES INC. $26.30 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113384
Principal investigator 1 SANOFI US SERVICES INC. $8,243.00 07/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113389
Principal investigator 1 Eli Lilly and Company $87,545.00 07/08/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187878389
Principal investigator 1 SANOFI US SERVICES INC. $745.00 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112425
Principal investigator 1 SANOFI US SERVICES INC. $9,427.90 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112455
Principal investigator 1 SANOFI US SERVICES INC. $940.00 07/02/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112467
Principal investigator 1 Genentech, Inc. $2,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583719
Principal investigator 1 Genentech, Inc. $1,001.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583721
Principal investigator 1 Genentech, Inc. $1,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583735
Principal investigator 1 Genentech, Inc. $16,501.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583745
Principal investigator 1 Genentech, Inc. $1,750.00 06/25/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
VELARITE No dispute reported 06/30/2026 1211583755
Principal investigator 1 SANOFI US SERVICES INC. $23,700.00 06/23/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113378
Principal investigator 1 SANOFI US SERVICES INC. $12,890.00 06/16/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Multinational, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group 48-week Extension Study to Evaluate the Treatment Response and Safety of Two Amlitelimab Dose Regimens Administered as Monotherapy by Subcutaneous Injection in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113330
Principal investigator 1 Novartis Pharmaceuticals Corporation $27,129.56 06/01/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH HOBOKEN
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190311253
Principal investigator 1 Eli Lilly and Company $11,785.36 05/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS No dispute reported 06/30/2026 1187876511
Principal investigator 1 SANOFI US SERVICES INC. $17,223.30 05/27/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113306
Principal investigator 1 Eli Lilly and Company $18,875.00 05/23/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187876693
Principal investigator 1 SANOFI US SERVICES INC. $23,910.20 05/12/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113263
Principal investigator 1 SANOFI US SERVICES INC. $2,810.60 05/12/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113295
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 05/05/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113164
Principal investigator 1 SANOFI US SERVICES INC. $915.90 05/05/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113207
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 05/05/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113243
Principal investigator 1 SANOFI US SERVICES INC. $11,274.00 04/28/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113156
Principal investigator 1 SANOFI US SERVICES INC. $6,637.02 04/28/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113216
Principal investigator 1 SANOFI US SERVICES INC. $120.00 04/28/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113256
Principal investigator 1 SANOFI US SERVICES INC. $130.00 04/14/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226113190
Principal investigator 1 ABBVIE INC. $1,250.00 04/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202469362
Principal investigator 1 SANOFI US SERVICES INC. $54,089.80 03/17/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112855
Principal investigator 1 SANOFI US SERVICES INC. $85.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112831
Principal investigator 1 SANOFI US SERVICES INC. $17.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112915
Principal investigator 1 SANOFI US SERVICES INC. $85.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112926
Principal investigator 1 SANOFI US SERVICES INC. $85.00 02/18/2025 Non-covered Recipient Entity
Care Access Research Llc
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evaluate the Efficacy and Safety of Amlitelimab Monotherapy by Subcutaneous Injection in Participants Aged 18 Years and Older With Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 1226112938
Principal investigator 1 Eli Lilly and Company $4,616.34 01/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876689
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,500.00 01/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190311133
Principal investigator 1 Eli Lilly and Company $122,799.00 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187876687